SCAR ZONE BURN GEL 0.13 % — DIN 02323966
BENZALKONIUM CHLORIDE : 0.13 % LIDOCAINE : 2.0 % · CCA INDUSTRIES, INC. · GEL · wholesale supply in Canada
Health Canada status: CANCELLED PRE MARKET
What is SCAR ZONE BURN GEL?
SCAR ZONE BURN GEL 0.13 % contains BENZALKONIUM CHLORIDE : 0.13 % LIDOCAINE : 2.0 %. It is listed in the Health Canada Drug Product Database under DIN 02323966, held by CCA INDUSTRIES, INC., supplied as GEL for TOPICAL administration. Health Canada currently lists it as cancelled pre market, status dated 09-Aug-2017. This Drug Identification Number is no longer authorized for sale in Canada, so Nexara does not supply it. The record is kept here because buyers still meet the number on old formularies, purchase orders and tender documents; Nexara can help identify an authorized alternative.
Is there a generic Lidocaine, Combinations in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
6 holders have a Canadian DIN containing Lidocaine, Combinations, across 7 DINs, of which 0 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| HUMN PHARMACEUTICALS INC | 2 | 0 | ITCH RELIEF CREAM, SUN BURN RELIEF CREAM | No marketed DIN |
| CANADIAN COLLEGE OF HOLISTIC HEALTH | 1 | 0 | SKIN SOOTHING AID | No marketed DIN |
| CCA INDUSTRIES, INC. | 1 | 0 | SCAR ZONE BURN GEL | No marketed DIN |
| EDGEWELL PERSONAL CARE CANADA, ULC | 1 | 0 | BURN RELIEF GEL | No marketed DIN |
| SANOFI CONSUMER HEALTH INC | 1 | 0 | ICY HOT LIDOCAINE PAIN RELIEVING CREAM PLUS MENTHOL | No marketed DIN |
| TENDER CORPORATION | 1 | 0 | PAIN RELIEVING CLEANSING SPRAY | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 0.13 % |
|---|---|
| Dosage form | GEL |
| Route | TOPICAL |
Pack detail is kept as a regulatory record. This DIN is no longer authorized for sale in Canada, so Nexara does not quote this pack.
Substance and classification
| Active substance | Lidocaine, Combinations |
|---|---|
| ATC code | D04AB51 |
| AHFS class | 84:04.92 ; 84:08.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02323966 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2323966 |
| Brand name | SCAR ZONE BURN GEL |
| Generic / active ingredient | BENZALKONIUM CHLORIDE : 0.13 % LIDOCAINE : 2.0 % |
| Market authorization holder | CCA INDUSTRIES, INC. |
| Health Canada schedule | NON-PRESCRIPTION DRUGS |
| ATC code | D04AB51 |
| ATC anatomical main group | D — Dermatologicals |
| ATC therapeutic subgroup | D04AB |
| Current status | CANCELLED PRE MARKET |
| Status date | 09-Aug-2017 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
0 of 7 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| BURN RELIEF GEL | 0.2 % | GEL | EDGEWELL PERSONAL CARE CANADA, ULC | CANCELLED POST MARKET | 02418150 |
| ICY HOT LIDOCAINE PAIN RELIEVING CREAM PLUS MENTHOL | 4 % | CREAM | SANOFI CONSUMER HEALTH INC | APPROVED | 02461447 |
| ITCH RELIEF CREAM | 0.5 % | CREAM | HUMN PHARMACEUTICALS INC | CANCELLED PRE MARKET | 02428091 |
| PAIN RELIEVING CLEANSING SPRAY | 2.5 % | SPRAY | TENDER CORPORATION | CANCELLED (UNRETURNED ANNUAL) | 02385236 |
| SKIN SOOTHING AID | 3 % | SOLUTION | CANADIAN COLLEGE OF HOLISTIC HEALTH | CANCELLED POST MARKET | 02501961 |
| SUN BURN RELIEF CREAM | 1.0 % | CREAM | HUMN PHARMACEUTICALS INC | CANCELLED PRE MARKET | 02428105 |
2 · Same class — other molecules in ATC D04AB
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Lidocaine | 2025-04-15 00:00:00 · AFTER SUN BURN RELIEF LIDOCAINE CONTINUOUS SPRAY · AFTER SUN GEL · AFTER SUN SOOTHING SPRAY · +112 more | 120 | 18 | Yes |
| Pramocaine | AVEENO ANTI-ITCH CREAM · AVEENO ANTI-ITCH LOTION · BACTINE PAIN RELIEVING CLEANSING SPRAY · BIKINI ZONE MEDICATED AFTER SHAVE SPRAY · +26 more | 36 | 7 | Yes |
| Benzocaine | ANIVY · BALZAROL ONT · BITE RELIEF · BOIL EASE DRAWING SALVE ONT · +24 more | 28 | 2 | Yes |
| Topical Anesthetics, Combinations | BURNCARE KIT · CETACAINE SPRAY · DERMACAINE-R · ONE TOUCH TOPICAL ANESTHETIC GEL · +3 more | 7 | 2 | Yes |
| Tetracaine | AMETOP GEL 4% · TETRACAINE2 · VIRACTIN GEL · VIRACTIN MOISTURIZING CREAM | 4 | 1 | Yes |
| Lidocaine, Combinations | BURN RELIEF GEL · ICY HOT LIDOCAINE PAIN RELIEVING CREAM PLUS MENTHOL · ITCH RELIEF CREAM · PAIN RELIEVING CLEANSING SPRAY · +3 more | 7 | 0 | Not in Canada |
| Cinchocaine | NUPERCAINAL ANTISEPTIC CREAM | 1 | 0 | Not in Canada |
| Benzocaine, Combinations | KAMA SUTRA PLEASURE BALM | 1 | 0 | Not in Canada |
| Anesthetics For Topical Use | TANAC MEDICATED GEL | 1 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC D04A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| D04AA | Diphenhydramine · Promethazine · Tripelennamine | 30 | 6 |
| D04AX | Other Antipruritics | 39 | 0 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled pre market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.